chrisvoncsefalvay/vaers-outcomes huggingface dataset:
About 8 hours after the injection, I developed hives in my mouth causing one side of my face to swell.   This lasted about 6 hours.  I started running a fever about 12 hours after the injection and it continued for 2 full days, fluctuating between 98.9 and 100.4.  In addition to the fever, I woke the morning after the injection with a slight headache, leg muscle pain, stopped up sinuses like a head cold, and no appetite.  All of these lasted about 18 hours.  There was a slight soreness at the injection sight the 1st night; but the soreness worsened the next day, moved down the arm muscle about a hand width below the injection site and became a hard and red feverish area the size of my palm.  It lasted about 3 days.
left arm itches alot, tingling, abdominal uncomfortable, feels like my respiratory isn't the same, tiredness, headaches everyday
First I felt weak, difficult to breath, fast but weak heart beats, then I had sudden extensive sweating from all over my body, then I fainted for maybe half a minutes.  I started to regain consciousness after that.  My son helped me to lie down in the sofa, and I was able to recover slowly after that without treatment.  My heart beat also gradually slowed down after that event, but it was still about 108/minute when I was in bed at around 5pm that day (about 5 hours after I fainted).
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 59-year-old male patient received BNT162b2 (BNT162B2), on 15May2022 as dose 4 (booster), single (Batch/Lot number: unknown), in right arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 10Nov2021 as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported.  The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Unknown Results; positive, notes: recurrence of fatigue and positive SARS-CoV-2 antigen test 7 days after finishing paxlovid. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: No other medication in 2weeks. Anti viral details was paxlovid, treatment start date was 28Jun2022, stop date was 02Jul2022, Indication=Treatment of COVID-19. No treatment for AE. No Known allergies. No Other medical history.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Had redness; Itches a little at injection; 4x2 oblong oval adjacent to the site of injection; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (Had redness), VACCINATION SITE PRURITUS (Itches a little at injection) and VACCINATION SITE RASH (4x2 oblong oval adjacent to the site of injection) in a 70-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 025L20A and 010M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ERYTHEMA (Had redness), VACCINATION SITE PRURITUS (Itches a little at injection) and VACCINATION SITE RASH (4x2 oblong oval adjacent to the site of injection). At the time of the report, ERYTHEMA (Had redness), VACCINATION SITE PRURITUS (Itches a little at injection) and VACCINATION SITE RASH (4x2 oblong oval adjacent to the site of injection) outcome was unknown.            concomitant medications  were not reported  Treatment was not specified
w/in 5 mins of receiving vax pt devel a red, spotted rash on lower & upper legs & lower back; no hives or difficulty breathing; rash disappeared;
Initial report received on 20 September 2011 from a health professional. A 90 year old female patient, whose medical history and concomitant medications were not reported, received a dose of FLUZONE HIGH DOSE (lot number not reported) on an unspecified date. An unspecified amount of time later, the patient had complaints of aches and pains and she had passed out when trying to get out of bed. The day following vaccination, she was hospitalized and was there for three days. The patient's outcome was not reported. The reporter for this case is the same as for case number 2011-09075. Documents held by sender: None.
ADMITTED TO HOSPITAL ON 08/12/2021 FOR + COVID, RESPIRATORY DISTRESS WITH O2 SATURATION 75% ON CPAP, ALSO TRANSPORTED WITH A-FIB.
A mother reported that her 9 month old daughter received Prevnar and DTAP vaccines on 10/31/00. Approx. 1 week, post vax, she became "severely sick". She had a bright red rash from head to toe and was itchy. The rash went down her throat. She developed irritability, fevers above 103F, congestion, pink eye and was hard to wake up. As of 2/5/01, she had the rash again, and was congested. Additional information received from the physician on 03/13/2001 indicated that a diagnosis of right otitis media and sinusitis were made. The patient was treated with amoxicillin and recovered.
redness around the injection site; swelling around the injection site; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE ERYTHEMA (redness around the injection site) and INJECTION SITE SWELLING (swelling around the injection site) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 vaccination.     Concurrent medical conditions included Atrial fibrillation. Concomitant products included METOPROLOL TARTRATE, ATORVASTATIN CALCIUM (ATORVASTATIN +PHARMA), OMEPRAZOLE SODIUM (OMEPRAZOLE [OMEPRAZOLE SODIUM]) and COLECALCIFEROL (D) for an unknown indication.    On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Jan-2021, the patient experienced INJECTION SITE ERYTHEMA (redness around the injection site) and INJECTION SITE SWELLING (swelling around the injection site). The patient was treated with LORATADINE (CLARITINE) at an unspecified dose and frequency; VITAMINS NOS (MULTIVITAMINUM) at an unspecified dose and frequency and BIOTIN at an unspecified dose and frequency. At the time of the report, INJECTION SITE ERYTHEMA (redness around the injection site) and INJECTION SITE SWELLING (swelling around the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the onset date of the reported events, a causal relationship cannot be excluded.
covid 19; This is a spontaneous report received from Sponsored Program, via a contactable male consumer (patient). A male patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot number and expiration date unknown) via an unspecified route of administration on 20Feb2021 at single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient was tested positive for COVID-19 last 27Feb2021. He was asking if it's okay for him to get the second vaccine on 13Mar2021. The outcome of the event was unknown.  Information on the lot/batch number has been requested.
After I got the first vaccine at my job  on  12/26/20  at 16:00. I got allergic  reaction with itchy  skin  and rash all over my body.  I  called to my doctor office to see her so she can  look my  rash.  She  wrote  me some Prednisone for my rash.  Should I get second Covid19  shot or not?  Because  I am really scared with this  reaction. I am looking forward to hear from  you.  Was this  is most common side affect that people got from the first Pfizer vaccine??
Chills, fever of 102.2, lasted 24 hours.  Outcome: blisters on face below nose, on upper and lower lips, and chin area only on the right side of face.  Blisters still healing as of this date, .
Fever up to 101.2 beginning 10 hrs post vaccine, resolved 48 hrs post vaccine Tachycardia (135 BPM, normal heart rate 70-75) and palpitations x 2 days, body aches, chills, nausea,  headache, skin sensitive to the touch, malaise., muscle twitching at vaccine site 1 day later, muscle weakness overall x 2 days, soreness at injection site x 3 days (tolerable)
Entire body was numb at approximately 9:00PM. 3 days after my left side of the face is partially numb.
This case was reported by a pharmacist and described the occurrence of nonspecific reaction in a subject of unspecified age and gender who was vaccinated with FLULAVAL (GlaxoSmithKline). On an unspecified date the subject received unspecified dose of FLULAVAL (unknown). At an unspecified time after vaccination with FLULAVAL, the subject experienced nonspecific reaction. At the time of reporting the outcome of the event was unspecified.
Patient received vaccines on 3/12/2012. Mom called the following morning to report hives. Doctor recommended BENADRYL for itching and TYLENOL for discomfort. Told to call if symptoms worsened.
48 hours after the vaccination, I woke up with itchiness at the injection site (lasted one day) and a localized reaction showing as red irritation and swelling extending approximately 3 inches underneath the injection site and approximately an inch wide. Area was tender like a bruise. Twenty-four hours later, area was no longer red and tender but was now itchy. On day 4, all itchiness and redness is gone.
Parent came into clinic on Tuesday, October 20 for a rash over entire body surface of child.  Per mom, rash started on Friday, 10/16/2020.  Mom thought it was due to vaccines received on 10/07/2020.  Mom was instructed to return to clinic if patient rash got worse:  May apply aloe vera/vitamin E lotion to body.  Return to clinic if symptoms worsen.
Person received an injection of covid-19 vaccine. She sat down for 15 minutes. Tingling began in left arm, and person felt slight lightheadedness during observation. As person arose from chair, tingling in left arm began to increase and she asked healthcare worker if the tingling  was normal. Worker stated "I think so". Friend then aided person as she began to fall to floor - person then placed on stretcher and became unconscious. EMTs times two were summoned to stretcher and they placed heart monitor and blood pressure cuff on person. Person was transferred to the Health Center - upon transfer, person became conscious and felt a heaviness on left side of body. Able to ambulate to BR and felt heaviness of left side of body. Bloodwork and CT scan were performed at FCHC and person reported as normal. It was decided by ER Doctor to transfer person to Hosp. Blood was drawn every so often and MRI was performed which person stated was all normal. Hosp. staff kept person overnight for observation. At approximately 2000 on 2/27/2021, person states that she felt back to normal with tingling of left arm subsided. Person was released early afternoon on Sunday, February 28th, 2021 after Doctor assessed person.
no additional AEs reported; GARDASIL 9 were administered to multiple unknown patients following temperature excursion; This non-valid, spontaneous report was received from an office manager and referred to multiple patients of unknown age and gender. The patients' concurrent conditions, concomitant therapies and medical history was not provided.  On an unknown date, multiple patients were vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.On unknown dates, the doses of vaccines experienced the temperature excursions of 8.55 Celsius degrees for 8 minutes and 9.29 Celsius degrees for 12 minutes (product storage error). There were no previous excursions reported. No additional adverse event (AE) details were reported (no adverse event).  This report is non-valid due to lack of patients' identifiers.  Follow-up information was received from an office manager on 10-MAY-2023:  The patient identifiers was updated such as date of birth, address and gender.  On 28-NOV-2022, the patient was vaccinated with one dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.  Temperature excursion total time was 25 minutes. There was 3 temperature excursions: on 09-SEP-2022 for 8 minutes, on 16-SEP-2022 for 5 minutes and on 03-JAN-2023 for 12 minutes. Excursions were not noted until after the first fact due to employee error of cleaning data logger more than once a day.  The vaccines was purhased with public and privet founds and were given in private doctor's office/ hospital.The medication error occurred in the point of storage in clinical practice.  This is one of several reports received from the same reporter. ; Sender's Comments:  US-009507513-2304USA002221:
Benedryl as needed. Multiple crops. Erythemadus with base vesicle.
Given a dose of Moderna vaccine  from a vial which was opened @ 1.55 pm the previous day; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT ADMINISTRATION ERROR (Given a dose of Moderna vaccine  from a vial which was opened @ 1.55 pm the previous day) in a 38-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Jun-2021, the patient experienced PRODUCT ADMINISTRATION ERROR (Given a dose of Moderna vaccine  from a vial which was opened @ 1.55 pm the previous day). At the time of the report, PRODUCT ADMINISTRATION ERROR (Given a dose of Moderna vaccine  from a vial which was opened @ 1.55 pm the previous day) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication were reported No treatment medication were reported.
I started feeling joint pain in my legs and ankle and was unable to move it to the right. I still have the pain and it is painful with symptoms. I put warm compresses and lotions on it to soothe the pain but it is still ongoing.
Administration of expired vaccine; This spontaneous case was reported by a health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administration of expired vaccine) in a 39-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Nov-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administration of expired vaccine). On 18-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Administration of expired vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant medication was reported.     No treatment medications were reported.
Large red rash/hive arose surrounding the injection site about 5 days after receiving second dose. Raised, warm, painful to the touch. Approximately 6-8 inches in diameter. No other adverse symptoms.
Burning sensation thru arm. Shot location swelled up to size of baseball  24-40 hours after shot: extreme pain in left arm joins below the shot including wrist and knuckles. Elbow felt like it was consistently being hit in the funny bone
This case was reported by a pharmacist via call center representative and described the occurrence of itchy rash in a 62-year-old male patient who received SHINGRIX (batch number L7F7E, expiry date 22nd November 2020) for prophylaxis. On 13th July 2018, the patient received the 1st dose of SHINGRIX (intramuscular) .5 ml. On 15th July 2018, 2 days after receiving SHINGRIX, the patient experienced itchy rash. On an unknown date, the outcome of the itchy rash was unknown. It was unknown if the reporter considered the itchy rash to be related to SHINGRIX. Additional details were reported as follows: The health care professional (HCP) reported that the patient received a dose of SHINGRIX and then 2 days later developed a rash in the right groin area. The patient went to see a doctor for this event. The rash was itchy but it was not painful so they did not think it was a shingles.
p/vax pt devel a macular rash @ the site of vax & was seen by MD 4/24/99;
8 days after injection as noted above, pt developed red, raised, warm area over her right deltoid, approx. 5x9cm
Bent over raised back up had a head rush foggy light headed balance problem almost 5 weeks ago and symptoms have not cleared.
polymyalgia rheumatica; Information has been received from a lawyer referring to a male patient of unknown age regarding a case in litigation. Information about concurrent condition, history condition and concomitant medication was not reported. On an unknown date, the patient was inoculated with zoster vaccine live (ZOSTAVAX) (strength, dose, route, lot# and expiration date unknown) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). After receiving zoster vaccine live (ZOSTAVAX), the patient suffered polymyalgia rheumatica. As a result of these symptoms, the patient was seen and treated by medical providers and was still under their care. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient's symptoms had resulted in physical limitations not present prior to using the vaccine. The patient also experienced mental and emotional distress due to resulting physical limitations and seriousness of the condition. As a result of the manufacture, marketing, advertising, promotion, distribution and/or sale of zoster vaccine live (ZOSTAVAX), the patient sustained severe and permanent personal injuries. Further, as a tragic consequence of zoster vaccine live (ZOSTAVAX), the patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient has suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of polymyalgia rheumatica was considered to be not recovered and causal relationship was assessed as related.    The lawyer considered the event polymyalgia rheumatica to be disability.  Upon internal review, polymyalgia rheumatica was determined to be medically significant.
Very irritable and crying, rash on chest 2 days later. 2 weeks later eyes rolling into back of head.  Personality change since this vaccine. No eye contact. Not engaged or responding to her name or other attempts to get her attention.
Parents report that child developed jerking/twitching movements of head and upper extremities that were described as "flailing", associated with altered breathing and dysconjugate gaze. No fever. No unresponsiveness.
WALKING DIFFICULTY/COULD BARELY WALK 2 STEPS FROM ONE ROOM TO ANOTHER; TIRED; JOINT PAIN IN ELBOWS AND KNEES; PROBLEM SLEEPING; NOT MUCH APPETITE/COULD NOT EAT ANYMORE; This spontaneous report received from a patient concerned a male of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 042A21A, and expiry: UNKNOWN) dose was not reported, administered on 02-APR-2021 for prophylactic vaccination. No concomitant medications were reported.  On 02-APR-2021, the subject experienced problem sleeping. On 02-APR-2021, the subject experienced not much appetite/could not eat anymore. On 02-APR-2021, the subject experienced joint pain in elbows and knees. On an unspecified date, the subject experienced walking difficulty/could barely walk 2 steps from one room to another, and tired. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from tired, and the outcome of joint pain in elbows and knees, problem sleeping, not much appetite/could not eat anymore and walking difficulty/could barely walk 2 steps from one room to another was not reported. This report was non-serious.
Patient became symptomatic on 3/22/2019 with rash around head and had a fever of around 100F.  Rash spread to trunk on 3/23 and then the rest of the body on 3/24.  His fever disapated after 3/22.   Patient was seen at Urgent Care on 3/24 where he was tested for measles.    Rash had mostly disapeared by 3/26.
Pt staes "she went to urgent care about 24 hours after Shingrix vaccination on 7/1/21 due to complaints of very violent tremors, nausea, chills, numb tongue. Was seen and discharged on Ibuprofen 800mg . Pt states on 7/2 she is tired and doesn't feel well overall still. Now has pain and achiness in left arm from shoulder to elbow and radiating around to upper back shoulder blade area"
sore arm; a little tired / took the day off from work; This spontaneous case was reported by a nurse and describes the occurrence of PAIN IN EXTREMITY (sore arm) and FATIGUE (a little tired / took the day off from work) in a 44-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 23-Jun-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Jun-2021, the patient experienced PAIN IN EXTREMITY (sore arm) and FATIGUE (a little tired / took the day off from work). At the time of the report, PAIN IN EXTREMITY (sore arm) and FATIGUE (a little tired / took the day off from work) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment information was provided by the reporter.